1-苄基-4-氰基哌啶 | 62718-31-4

• 物质功能分类: 化学试剂 - 有机试剂 - 氰酸酯/异氰酸酯
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-苄基-4-氰基哌啶
• 中文别名: 1-苄基哌啶-4-甲腈
• 英文名称: 1-benzylpiperidine-4-carbonitrile
• 英文别名: 1-(phenylmethyl)-4-piperidinecarbonitrile
• CAS: 62718-31-4
• 化学式: C₁₃H₁₆N₂
• 分子量: 200.283
• InChiKey: CKJUFUGVCGDYHH-UHFFFAOYSA-N

物化性质

• 沸点：
  330.3±35.0 °C(Predicted)
• 密度：
  1.06

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Benzylpiperidine-4-carbonitrile
Synonyms: 1-Benzyl-4-cyanopiperidine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Benzylpiperidine-4-carbonitrile
CAS number: 62718-31-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H16N2
Molecular weight: 200.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

1-苄基-4-氰基哌啶 概述

1-苄基-4-氰基哌啶是一种有机中间体，可以通过两种方法制备：一种是通过哌啶-4-甲酰胺和苄基溴在乙醇中反应得到1-苄基-4-羰基酰胺哌啶，再经步骤二转化为目标产物；另一种则是直接将4-氰基哌啶与苯甲醛进行还原胺化反应。

应用

该化合物广泛用于有机合成中间体及医药领域，在实验室研发和化工医药研究中具有重要应用价值。

制备 步骤1：制备中间体 1-苄基-4-羰基酰胺哌啶

在搅拌悬浮液中，将哌啶-4-甲酰胺（16.5 g, 0.13 mol）和碳酸钾（K₂CO₃，35.6 g, 0.26 mol）溶解于乙醇（EtOH，350 ml）中。随后加入苄基溴（22.0 g, 0.13 mol），加热至回流状态维持3小时。冷却至室温后过滤，减压蒸发滤液，并用水（H₂O，200 ml）稀释。使用氯仿（CH₂Cl₂，3×150 ml）萃取水层，合并有机相并用无水硫酸钠（Na₂SO₄）干燥。再次进行溶剂的真空蒸发，得到白色固体产物（20.0 g, 71.0%）。

步骤2：制备中间体 1-苄基-4-氰基哌啶

将步骤一所得产物1-苄基-4-羰基酰胺哌啶（20.0 g，91.7 mmol），与五氧化二磷（P₂O₅, 16.92 g, 119.2 mmol）混合，在氩气保护下于180-200°C加热3小时。冷却至室温后加入水（H₂O，150 ml），小心添加碳酸钾（K₂CO₃）使溶液碱化。之后使用乙酸乙酯（EtOAc，3×150 ml）进行萃取。有机相经无水硫酸钠干燥、过滤及溶剂的真空蒸发后得到黄色油状物产物（16.7 g, 90.9%）。

反应信息

• 作为反应物：
  描述：

  1-苄基-4-氰基哌啶 在 二异丁基氢化铝 、 水 、 sodium hydroxide 作用下， 以 甲苯 、 甲醇 为溶剂， 反应 1.5h， 以97.5%的产率得到1-苄基-4-哌啶甲醛
  参考文献：
  名称：

  N-苄基-4-哌啶甲醛的合成方法

  摘要：

  本发明属于药物合成技术领域，具体涉及一种N‑苄基‑4‑哌啶甲醛的合成方法。以4‑哌啶甲酸为原料，经酯化反应生成4‑哌啶甲酸甲酯盐酸盐，4‑哌啶甲酸甲酯盐酸盐经烷基化反应生成N‑苄基‑4‑哌啶甲酸甲酯，N‑苄基‑4‑哌啶甲酸甲酯水解得到N‑苄基‑4‑哌啶甲酸，N‑苄基‑4‑哌啶甲酸经酰化反应生成N‑苄基‑4‑哌啶甲酰胺，N‑苄基‑4‑哌啶甲酰胺脱水得到1‑苄基哌啶‑4‑腈，1‑苄基哌啶‑4‑腈经还原反应生成N‑苄基‑4‑哌啶甲醛。本发明方法反应条件温和，后处理简单，而且收率较高，在0℃就能以高收率得到N‑苄基‑4‑哌啶甲醛，不需要柱层析，且重复性高。

  公开号：

  CN111484444B
• 作为产物：
  描述：

  1-苄基哌啶-4-羧酰胺 在 氯化亚砜 作用下， 反应 3.0h， 以73%的产率得到1-苄基-4-氰基哌啶
  参考文献：
  名称：

  一些新的喹唑啉衍生物的合成及其降压活性。

  摘要：

  合成了一系列取代的2-哌啶子基-4-氨基-6,7-二甲氧基喹唑啉，并将其筛选为潜在的降压药。在氨基甲酸乙酯麻醉的正常血压大鼠中静脉内给药后，研究了所有新化合物的降压作用。吡唑嗪分子中的呋喃基哌嗪部分可以被更稳定的取代哌啶基团取代，而不会降低血压降低活性。然而，取代基的性质深刻影响了降压效力以及降压作用的持续时间。发现一些新化合物与哌唑嗪一样有效。根据麻醉大鼠的效力和降压作用的持续时间，选择了五个最有希望的化合物进行进一步研究。这些药物中的每一种在有意识的自发性高血压大鼠中通过口服给药都具有降压作用。在小剂量时，新化合物似乎不如哌唑嗪有效，但在10-100μmol/ kg的较高剂量下，其中两种似乎比哌唑嗪更有效。

  DOI：

  10.1021/jm00364a014

文献信息

• [EN] FURO[3,2-d]PYRIMIDINE COMPOUNDS<br/>[FR] COMPOSÉS DE FURO[3,2-D]PYRIMIDINE
  申请人：ABBOTT LAB

  公开号：WO2012048222A1

  公开（公告）日：2012-04-12

  The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof wherein the variables are defined as herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

  本发明涉及式(I)的新化合物、药用可接受的盐、生物活性代谢物、前药、外消旋混合物、对映异构体、非对映异构体、溶剂合物和水合物，其中变量如本文所述定义。式(I)的化合物作为激酶抑制剂是有用的，因此可用于治疗某些状况和疾病，特别是炎症状况和疾病以及增殖性障碍和状况，例如癌症。
• Piperidinylalkyl quinazoline compounds, composition and method of use
  申请人：Janssen Pharmaceutica, N.V.

  公开号：US04335127A1

  公开（公告）日：1982-06-15

  Novel quinazoline derivatives, comprising in the heterocyclic part of their quinazoline nucleus at least one carbonyl or thiocarbonyl group and a particularly substituted piperidinyl-alkyl side chain, said compounds being potent serotonin-antagonists.

  新型喹唑啉衍生物，在其喹唑啉核的杂环部分至少含有一个羰基或硫代羰基基团和一个特异取代的哌啶基烷基侧链，所述化合物是有效的5-羟色胺拮抗剂。
• Catalytic C(sp²)–C(sp³) Bond Formation of Methoxyarenes by the Organic Superbase <i>t</i>-Bu-P4
  作者：Masanori Shigeno、Kazutoshi Hayashi、Kanako Nozawa-Kumada、Yoshinori Kondo

  DOI：10.1021/acs.orglett.0c03507

  日期：2020.11.20

  [cyano, nitro, (non)enolizable ketone, chloride, and amide moieties] are allowed on methoxyarenes. Moreover, an array of alkanenitriles with/without an aryl moiety at the nitrile α-position can be employed. The system also features no requirement of a stoichiometric base, MeOH (not salt waste) formation as a byproduct, and the production of congested quaternary carbon centers.

  有机超碱催化剂t -Bu-P4实现了烷烃前亲核体对甲氧基芳烃的亲核芳族取代。在甲氧基芳烃上可以使用各种官能团[氰基，硝基，（不可）烯化的酮，氯和酰胺部分）。此外，可以使用在腈α-位具有/不具有芳基部分的链烷腈的阵列。该系统还不需要化学计量的碱，不需要的副产物MeOH（无盐废料）形成以及拥挤的季碳中心的生产。
• [EN] SUBSTITUTED 3- AND 4- AMINOMETHYLPIPERIDINES FOR USE AS BETA-SECRETASE IN THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] 3- ET 4- AMINOMETHYLPIPERIDINES SUBSTITUEES UTILISEES COMME BETA-SECRETASE DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2004002483A1

  公开（公告）日：2004-01-08

  The invention relates to novel compounds, which are substituted chiral or achiral derivatives of 3- or 4- aminomethylpiperidine of the general formula (I). The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of general formula (I) and especially their use as inhibitors of beta-secretases for the treatment of Alzheimer’s disease.

  本发明涉及新型化合物，其为通式（I）的3-或4-氨基甲基哌啶的取代手性或非手性衍生物。本发明还涉及包括制备这些化合物的工艺、含有一种或多种通式（I）化合物的药物组合物以及特别是它们作为β-分泌酶抑制剂用于治疗阿尔茨海默病的相关方面。
• Benzopiperidine derivatives
  申请人：Eisai Co., Ltd.

  公开号：US06518423B1

  公开（公告）日：2003-02-11

  Benzopiperidine derivatives represented by formula (I), salts thereof or hydrates thereof, processes for producing the same and drugs comprising the same: wherein the variables are as described in the specification. These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and rejection reaction accompanying organ transplantation.

  本茨哌啶衍生物，由公式(I)表示，其盐或水合物，其制备方法以及包含其的药物: 其中变量如说明书中所述。这些化合物作为药物有效，用于预防和治疗这些各种炎症性疾病和免疫性疾病，如类风湿性关节炎、特应性皮炎、银屑病、哮喘和伴随器官移植的排斥反应。